News & Updates

GLP-1 RA plus SGLT-2i better than monotherapy for CV, renal events prevention
GLP-1 RA plus SGLT-2i better than monotherapy for CV, renal events prevention
04 May 2024 byStephen Padilla

Patients with type 2 diabetes (T2D) who received combined treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have a much lower risk of major adverse cardiovascular events (MACE) and serious renal events than those treated with either drug class alone, suggests a recent study.

GLP-1 RA plus SGLT-2i better than monotherapy for CV, renal events prevention
04 May 2024
Plant-based diets help lower risk of prostate cancer progression
Plant-based diets help lower risk of prostate cancer progression
04 May 2024

Men with prostate cancer who consume higher amounts of plant-based foods have a lower risk of cancer progression, as shown in a longitudinal observational cohort study.

Plant-based diets help lower risk of prostate cancer progression
04 May 2024
Semaglutide benefits extend to HFpEF patients with T2D
Semaglutide benefits extend to HFpEF patients with T2D
04 May 2024
Sexual problems remain a burden in breast cancer patients
Sexual problems remain a burden in breast cancer patients
03 May 2024

Sexual disorders are common among breast cancer patients, and such problems may continue for up to 2 years after the cancer diagnosis, according to a study. Notably, a communication gap regarding sexuality persists between patients and healthcare providers.

Sexual problems remain a burden in breast cancer patients
03 May 2024